Brian Yang
Managing Editor
![](/-/media/staff-photos/brian-yang-round.png?rev=6776c49e1df443e8843371c125a40c05)
Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.
Latest From Brian Yang
RemeGen Rises, Falls Along With Chinese Antibody Ambitions
Everything seemed to be aligned for success, but shares in leading Chinese antibody developer RemeGen recently dropped by nearly 40%, reflecting a range of internal and external likely factors.
Mounjaro Approval Takes Global Obesity Battle To China
The global battle of the blockbuster obesity drugs appears set to come to China with the approval of Lilly's Mounjaro, although domestic competitors are fast catching up.
EU Confidence In China Market Still On Downward Trend
The anticipated business rebound for China after its post-COVID reopening of markets in 2023 has not materialized and structural market issues continue to affect EU firms' China sentiment.
Legend Buyout Report Boosts, Validates China Biotech
A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.
Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global?
The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.
EU Firms' China Sentiment Plummets, China Go-Global Push Hits Reality Check
China's deepening economic downturn is impacting foreign business confidence in China, while recent high-profile events have created uncertainties around the go-global push by Chinese pharma firms, at a time when this has become critical to their very survival.